Annex A: Target Product Profile (TPP) on Specifications
for Unmet Needs in Dengue, Hepatitis B, Malaria,
and Tuberculosis
1. Dengue TPP:
- Lateral flow point-of-care (POC) detection of NS1 for early fever (1st 5 days onset)
- Lateral flow POC for IgG and IgM after 5 days of 1st onset PCR based test for dengue serotypes for surveillance
- Diagnostics for secondary infection to identify suitable vaccine
- Further TPP info: https://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf
2. Hepatitis B TPP:
3. Malaria TPP:
4. Tuberculosis TPP:
- Rapid point-of-care non-sputum-based test capable of detecting all forms of TB by identifying characteristic biomarkers or biosignatures
- Rapid triage TB test which is point-of-care that should be a simple, low-cost test that can be used by first-contact health-care providers to identify those who need further testing
- Rapid test for drug susceptibility that can be used at the microscopy-centre level of the health-care system to select first-line regimen-based therapy (the rapid DST test).
- The following anti-TB agents should be included in resistance testing at the microscopy level (they are presented in order of decreasing priority):
- rifampicin
- fluoroquinolones (including moxifloxacin)
- isoniazid and pyrazinamide
- Further TPP: https://www.who.int/tb/publications/tpp_report/en/